A Monte Carlo model of synchrotron radiotherapy shows good agreement with experimental dosimetry measurements: Data from the imaging and medical beamline at the Australian Synchrotron. (September 2020)

• Record Type: Journal Article
• Authors: Day, L.R.J.; Pellicioli, P.; Gagliardi, F.; Barnes, M.; Smyth, L.M.L.; Butler, D.; Livingstone, J.; Stevenson, A.W.; Lye, J.; Poole, C.M.; Hausermann, D.; Rogers, P.A.W.; Crosbie, J.C.
• Is Part Of: Physica medica. Volume 77(2020)
• Page Start: 64
• Page End: 74
• Publication Date: 2020-09
• Subjects: Monte Carlo -- Synchrotron -- Microbeam radiotherapy; Medical physics -- Periodicals; Biophysics -- Periodicals; Biophysics -- Periodicals; Imagerie médicale -- Périodiques; Radiothérapie -- Périodiques; Rayons X -- Sécurité -- Mesures -- Périodiques; Physique -- Périodiques; Médecine -- Périodiques; 610.153
• DOI: 10.1016/j.ejmp.2020.07.017
• Languages: English
• ISSNs: 1120-1797

Abstract

Highlights: MC simulations shows good agreement to SyncRT measured doses. Our MC model serves as a validation tool for SyncRT dose calculation. The Synchrotron source size has an important effect on the MRT dose distribution. Abstract: Experimental measurement of Synchrotron Radiotherapy (SyncRT) doses is challenging, especially for Microbeam Radiotherapy (MRT), which is characterised by very high dynamic ranges with spatial resolutions on the micrometer scale. Monte Carlo (MC) simulation is considered a gold standard for accurate dose calculation in radiotherapy, and is therefore routinely relied upon to produce verification data. We present a MC model for Australian Synchrotron's Imaging and Medical Beamline (IMBL), which is capable of generating accurate dosimetry data to inform and/or verify SyncRT experiments. Our MC model showed excellent agreement with dosimetric measurement for Synchrotron Broadbeam Radiotherapy (SBBR). Our MC model is also the first to achieve validation for MRT, using two methods of dosimetry, to within clinical tolerances of 5% for a 20 × 20 mm 2 field size, except for surface measurements at 5 mm depth, which remained to within good agreement of 7.5%. Our experimental methodology has allowed us to control measurement uncertainties for MRT doses to within 5–6%, which has also not been previously achieved, and provides a confidence which until now has been lacking in MRT validation studies. The MC model is suitable for SyncRT dose calculation of clinically relevant field sizes at the IMBL, and can be extended to include medical beamlines at other Synchrotron facilities as well. The presented MC model will be used as a validation tool for treatment planning dose calculation algorithms, and is an important step towards veterinary SyncRT trials at the Australian Synchrotron.